Biocept Expands Commercial Offering Of CNSide Assay To Most Cancers That Metastasize To The Central Nervous System
Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products, and services, announces the expanded commercial availability of CNSide for patients with metastatic melanoma.
